Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Synaptogenix to Hold

Maxim Group Downgrades Synaptogenix to Hold

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.

Analyst Ratings

Analyst Ratings for AerCap Holdings

By Benzinga Insights

May 3, 2:01 PM

AerCap Holdings (NYSE:AER) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

AER

News

CEL-SCI Files Request With The UK’s MHRA Regarding Path To Approval For Multikine In The Treatment Of Head & Neck Cancer

By Benzinga Newsdesk

October 5, 8:47 AM

CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantages that are superior to those published by CEL-SCI previously, as a result of an improved selection

CVM

Analyst Ratings

What 4 Analyst Ratings Have To Say About Cardlytics

By Benzinga Insights

June 6, 4:02 PM

Analysts have provided the following ratings for Cardlytics (NASDAQ:CDLX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CDLX

Teladoc Financials Impress in Q2: Analysts Optimistic On Q2 Performance But Stay On Sidelines

By Vandana Singh

July 26, 2:17 PM

Teladoc Health Inc (NYSE: TDOC) shares are trading higher after the company reported better-than-expected

TDOC

Maxim Group Downgrades Synaptogenix to Hold

Related Posts

Analyst Ratings for AerCap Holdings

CEL-SCI Files Request With The UK’s MHRA Regarding Path To Approval For Multikine In The Treatment Of Head & Neck Cancer

What 4 Analyst Ratings Have To Say About Cardlytics

Teladoc Financials Impress in Q2: Analysts Optimistic On Q2 Performance But Stay On Sidelines